Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Twist Bioscience Corp TWST

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of... see more

NDAQ:TWST - Post Discussion

Twist Bioscience Corp > 7 THINGS YOU SHOULD KNOW ABOUT TWIST BIOSCIENCE CORPORATION!
View:
Post by AviseAnalytics on Jun 13, 2022 7:26am

7 THINGS YOU SHOULD KNOW ABOUT TWIST BIOSCIENCE CORPORATION!

$TWST

Twist Biosciences, Inc. (NASDAQ: TWST) manufactures and sells synthetic DNA-based products by leveraging the Company’s DNA synthesis platform that helps write DNA on a silicon chip.
 
Here are 7 things you should know about the Company!
 

Read on to know more:

https://www.aviseanalytics.com/7-things-you-should-know-about-twist-bioscience-corporation/

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities